News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
US FDA Warns of Muscle Harm When Ingredients in Heart Drugs Merck & Co., Inc., Abbott Laboratories Combine
August 8, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Aug 8 (Reuters) - U.S. health officials warned the public on Friday about the risk of a rare type of muscle injury seen when the cholesterol drug simvastatin is combined with the anti-arrhythmia medicine amiodarone.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Merck & Co.
Food and Drug Administration (FDA)
Abbott Laboratories
MORE ON THIS TOPIC
Schizophrenia
Atai-Partnered Schizophrenia Drug Flunks Mid-Stage Trial
July 28, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Eli Lilly Commits $856M in Biobucks to Gate Bioscience for New Class of Medicines
July 25, 2025
·
1 min read
·
Dan Samorodnitsky
Autoimmune disease
AstraZeneca Claims PIII Win With Nanobody Treatment for Myasthenia Gravis
July 24, 2025
·
2 min read
·
Dan Samorodnitsky
I&I
Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint
July 24, 2025
·
2 min read
·
Dan Samorodnitsky